内容紹介
An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy
Summary
S-1 is one of the effective chemotherapy regimens for treating non-small cell lung cancer. We report of an elderly patient with non-small cell lung cancer who responded to S-1 monotherapy following gefitinib therapy. An 83-year-old woman was diagnosed with advanced adenocarcinoma of the lungs(cT3N3M1a, Stage Ⅳ). Considering her age, monotherapy with vinorelbine was administered as first-line chemotherapy. Despite the completion of four courses, she was diagnosed with progressive disease. Thereafter, after considering her status as a non-smoking woman, gefitinib was introduced as second-line chemotherapy, which resulted in significant tumor size reduction. Tumor regrowth was identified 16 months later, and gefitinib was switched to erlotinib, but the tumor kept increasing in size. S-1 monotherapy was introduced as fourth-line chemotherapy, and the tumor began to decrease in size again. A partial response was obtained after 10 months, without serious adverse effects. Gefitinib following S-1 monotherapy resulted in long-term tumor size control for a total of 27 months in an elderly patient with advanced non-small cell lung cancer. S-1 monotherapy might be one of the options for salvage therapy after gefitinib treatment becomes ineffective.
要旨
症例は83歳,女性。肺腺癌,cT3N3M1a,Stage Ⅳの診断となった。高齢であり,一次治療としてvinorelbine(25 mg/m2,day 1・8,静注)単剤治療を行うも腫瘍病変の増悪を認めた。gefitinib(250 mg/day,分1,経口)を投与し,約16か月間の長期間,病変の制御が維持された。増悪後,S-1(80 mg/day,分2,経口)単剤治療にて,再び著明な腫瘍縮小効果を認めた。gefitinibおよびその後のS-1単剤治療により高齢者ながら約27か月の長期生存が得られ,S-1治療がgefitinib耐性化後の後治療として有用である可能性が考えられた。
目次
Summary
S-1 is one of the effective chemotherapy regimens for treating non-small cell lung cancer. We report of an elderly patient with non-small cell lung cancer who responded to S-1 monotherapy following gefitinib therapy. An 83-year-old woman was diagnosed with advanced adenocarcinoma of the lungs(cT3N3M1a, Stage Ⅳ). Considering her age, monotherapy with vinorelbine was administered as first-line chemotherapy. Despite the completion of four courses, she was diagnosed with progressive disease. Thereafter, after considering her status as a non-smoking woman, gefitinib was introduced as second-line chemotherapy, which resulted in significant tumor size reduction. Tumor regrowth was identified 16 months later, and gefitinib was switched to erlotinib, but the tumor kept increasing in size. S-1 monotherapy was introduced as fourth-line chemotherapy, and the tumor began to decrease in size again. A partial response was obtained after 10 months, without serious adverse effects. Gefitinib following S-1 monotherapy resulted in long-term tumor size control for a total of 27 months in an elderly patient with advanced non-small cell lung cancer. S-1 monotherapy might be one of the options for salvage therapy after gefitinib treatment becomes ineffective.
要旨
症例は83歳,女性。肺腺癌,cT3N3M1a,Stage Ⅳの診断となった。高齢であり,一次治療としてvinorelbine(25 mg/m2,day 1・8,静注)単剤治療を行うも腫瘍病変の増悪を認めた。gefitinib(250 mg/day,分1,経口)を投与し,約16か月間の長期間,病変の制御が維持された。増悪後,S-1(80 mg/day,分2,経口)単剤治療にて,再び著明な腫瘍縮小効果を認めた。gefitinibおよびその後のS-1単剤治療により高齢者ながら約27か月の長期生存が得られ,S-1治療がgefitinib耐性化後の後治療として有用である可能性が考えられた。